A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health

This retrospective review of Ketamine-Assisted Psychotherapy (KAP) trial (n=1806) aimed to assess the effectiveness of KAP in adult patients dealing with mental health issues.

Conducted by Field Trip Health, the study took place across 11 clinics in North America. KAP involved 4-6 guided ketamine sessions with psychotherapy-only visits after specific doses.

The primary objective was to examine treatment effects at 1, 3, and 6 months relative to baseline on depression, anxiety, and post-traumatic stress outcomes. Self-reported measures were utilised to evaluate symptoms of depression, anxiety, and post-traumatic stress.

This study contributes to understanding the sustained real-world effects of Ketamine-Assisted Psychotherapy, which is of interest to various stakeholders including patients, clinicians, researchers, and policymakers.

Topic Anxiety Depression PTSD
Compound Ketamine
Country Canada United States of America
Visit trial
Status Completed
Results Published Yes
Start date 13 March 2020
End date 16 June 2022
Phase Phase IV
Design Open
Type Interventional
Generation First
Participants 1806
Sex All
Age 19- 99
Therapy Yes

Trial Details

Ketamine-Assisted Psychotherapy (KAP) is a relatively new approach for the treatment of mental health issues, which involves the combination of ketamine, a dissociative anaesthetic with psychedelic properties, and psychotherapy to promote emotional wellbeing. In this study, we investigated the effectiveness of KAP in adult patients coping with mental health. We predicted that clients would experience lasting reductions in psychological distress over time, such as depression, anxiety, and post traumatic stress, that would be detectable up to 6 months after treatment. The results of this study may provide evidence of sustained real-world effects of Ketamine-Assisted Psychotherapy, of interest to patients, clinicians, researchers, and policymakers.

Trial Number NCT05604794

Sponsors & Collaborators

Field Trip
Field Trip is a company that offers psychedelics therapies. It has several locations (US/CA) that provides ketamine-assisted therapy. It has raised $19.5M in Series A & B funding rounds.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.